← All trials
NCT04593940
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2020
- Primary completion
- Feb 28, 2021
- Completion date
- Sep 30, 2021
- First posted
- Oct 20, 2020
- Last posted
- Dec 16, 2020
- Enrollment
- 2160
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Duke UniversityLead sponsor
- Washington University in St. LouisStudy chair
- Duke UniversityOverall official - principal investigator
- Duke UniversitySponsor investigator
- Department of Health and Human ServicesCollaborator
- National Center for Advancing Translational Science (NCATS)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.